Enterome receives FDA Fast Track designation in follicular lymphoma for lead OncoMimics™ immunotherapy EO2463
Read more
23
June 2025
Enterome presents positive Phase 2 interim results in relapsed/refractory indolent non-Hodgkin lymphoma after EO2463 OncoMimics™ immunotherapy treatment at ICML
Read more
12
June 2025
Enterome raises $19 million to fund clinical development of its OncoMimics™ immunotherapy to treat Follicular Lymphoma
Read more
02
June 2025
Enterome to present positive Phase 2 indolent non-Hodgkin lymphoma data for its OncoMimics™ EO2463 at ICML
Read more
30
May 2025
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
Read more
11
December 2024
Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024
Read more
10
December 2024
Enterome’s Immunotherapy EO2463 Shows Early Clinical Response in Newly Diagnosed Follicular Lymphoma Suggesting a Potential Alternative to ‘Watchful Waiting’
Read more
13
November 2024
Enterome to host webinar on new clinical data from the ongoing Phase 1/2 ‘SIDNEY’ trial of lead programme, EO2463
Read more
06
November 2024
Enterome to Present New Clinical Data and Biomarker Findings for EO2463 at the 2024 American Society of Hematology (ASH) Annual Meeting
What is the future of next-generation immunotherapies for cancer ?
Read more
Presentations and posters
Scientific Presentations
Presentation of new clinical data from ongoing Phase 1/2 ‘SIDNEY’ trial of lead programme, EO2463
EO4010 (EO) + nivolumab (N) +/- bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)
R. Cohen, et al.
ESMO IO 2024
EO2463 Peptide Immunotherapy in Patients with Indolent NHL: A Phase 1 Exploration of a Response Biomarker for EO2463 Monotherapy and EO2463 in Combination with Lenalidomide/Rituximab
J. Caetano Villasboas, et al.
2024 ASH Annual Meeting
EO2463 Peptide Immunotherapy in Patients with Newly Diagnosed Asymptomatic Follicular Lymphoma Results in Monotherapy Objective Clinical Responses Linked with Anti-Peptide Specific CD8 Memory T Cell Responses
J. Caetano Villasboas, et al.
2024 ASH Annual Meeting
Novel immunotherapy based on commensal-derived peptides for driving an effective CD8+ T cell response against selected Tumor-Associated Antigens
A. Talpin, et al.
EACR 2024 Congress
Phase 1/2 of EO2463 immunotherapy as monotherapy and in combination with lenalidomide and/or rituximab in indolent NHL
J. Caetano Villasboas, et al.
2024 ASCO Annual Meeting
Gut microbiota mimics as a potential source of cross-reactive tumor rejection antigens
V. Panneton, et al.
2024 AACR Annual Meeting
EO2401 peptide immunotherapy + nivolumab +/- bevacizumab in first recurrent glioblastoma: the phase 1/2 EOGBM1-18/ROSALIE study
D. Reardon, et al.
2023 SNO Annual Meeting
Novel immunotherapy based on commensal-derived peptides to drive an effective CD8+ T cell response against selected Tumor-Associated Antigens
A. Talpin, et al.
SITC 2023 Annual Meeting
Relevant Literature
*authored by Enterome
OncoMimics approach
A Mimicry-Based Strategy Between Human and Commensal Antigens for the Development 2 of a New Family of Immune Therapies for Cancer
A. Talpin, et al.
Journal for ImmunoTherapy of Cancer
The good and the bad of T cell cross-reactivity: challenges and opportunities for novel therapeutics in autoimmunity and cancer
C. Gouttefangeas, et al.
Frontiers in Immunology, June 2023
*Drug discovery in the age of deep sequencing
C. Bonny
MedNous, May 2022
A very high level of crossreactivity is an essential feature of the T-cell receptor
D. Mason
Immunology today, September 1998
Cross-reactivity of T cells and its role in the immune system
G. Petrova, et al.
Critical Reviews in Immunology, March 2012
Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire
V. l. Zarnitsyna, et al.
Frontiers in Immunology, December 2013
Why must T cells be cross-reactive?
A. Sewell, et al.
Nature Reviews Immunology, August 2012
Challenges in the development of effective peptide vaccines for cancer
C. Buteau, et al.
Mayo Clinic Proceedings, April 2002
T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
M. Sioud, et al.
Scandinavian Journal of Immunology, January 2018
Pre-existing heterologous T-cell immunity and neoantigen immunogenicity
Q. Leng, et al.
Clinical & Translational Immunology, March 2020
Effector and Memory T cell Responses to Commensal Bacteria
Y. Belkaid, et al.
Trends Immunology, June 2013
EndoMimics approach
Bacterial Protein Mimetic of Peptide Hormone as a New Class of Protein- based Drugs
S. Fetissov, et al.
Current Medicinal Chemistry, October 2017
Gut microbiota in human metabolic health and disease
Y. Fan, et al.
Nature Reviews Microbiology, September 2020
IL-10 produced by macrophages regulates epithelial integrity in the small intestine
T. Morhardt, et al.
Scientific reports, February 2019
IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
W. Ouyang, et al.
Immunity, April 2019
Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease
Tomaro-Duchesneau, et al.
Scientific Reports, March 2020
Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Yoon, et al.
Nature Microbiology, April 2021
Mapping interactions of microbial metabolites with human G-protein-coupled receptors
Colosimo, et al.
Cell, Host & Microbe, August 2019
Computational platform
*GeneMark-HM: improving gene prediction in DNA sequences of human microbiome
A. Lomsadze, et al.
NAR Genomics and Bioinformatics, June 2021
*Scalable workflow and reproductible data analysis for genomics
F. Strozzi, et al.
Methods in molecular biology, July 2019
*MSP-Miner-abundance-based reconstitution of microbial pan-genomes from shotgun metagenomic data
F. Onate, et al.
Bioinformatics, May 2019
*A unified catalog of 204,938 reference’ genomes from the human gut microbiome
A. Almeida, et al.
Nature biotechnology, July 2020
*Incorporating phylogenetic information in microbiome differential abundance studies has no effect on detection power and FDR control
A. Bichat, et al.
Frontiers in microbiology, April 2020
A metagenomic strategy for harnessing the chemical repertoire of the human microbiome
Sugimoto, et al.
Science, December 2019
Microbiome connections with host metabolism and habitual diet from 1,098 deeply phenotyped individuals
Asnicar, et al.
Nature Medicine, January 2021
*Impact of laparoscopic Roux-enY gastric bypass and sleeve gastrectomy on gut microbiota – a metagenomic comparative analysis
W. Farin, et al.
Surgery for obesity and related diseases, March 2020
Focus on inflammatory diseases
*Identification of a muropeptide precursor transporter from gut microbiota and its role in preventing intestinal inflammation
S. Liuu, et al.
PNAS, December 2023
*Adlercreutzia equolifaciens Is an Anti-Inflammatory Commensal Bacterium with Decreased Abundance in Gut Microbiota of Patients with Metabolic Liver Disease
F.P. Oñate, et al.
International Journal of Molecular Sciences, September 2023
*Low-dose IL-2 shapes a tolerogenic gut microbiota that improves autoimmunity and gut inflammation
N. Tchitchek, et al.
JCI Insight, September 2022
*Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn's disease
G. Chevalier, et al.
Microbiome, August 2021
*Antimicrobial resistance profiles of adherent invasive Escherichia coli show increased resistance to B-lactams
M. Martinez-Medina, et al.
Antibiotics, May 2020
*Gut microbiota diversity is reduced in smokers with Crohn’s disease
J. Opstelten, et al.
Inflammatory bowel diseases, September 2016
Focus on the gut microbiome impact on human health
*Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in NAFLD
S. Burz, et al.
Microorganisms, January 2021
*The human gut microbiome as source of innovation for health: which physiological and therapeutic outcomes could we expect?
J. Doré, et al.
Therapy, February 2017
Downloads
MSPminer
The binary is freely available for non-commercial users
